Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Scott Biller
AddedFeb 13, 2024
UpdatedMay 31, 2026
Scott Biller

Scott Biller

Board Member, Foghorn Therapeutics

CrunchbaseLinkedIn

Scott Biller's Career

Foghorn Therapeutics
Foghorn Therapeutics

Cambridge, MA, US

Board Member· Board
Rome Therapeutics
Rome Therapeutics

Boston, MA, US

Board Member· Board
Remix Therapeutics
Remix Therapeutics

Watertown, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Scott Biller's Career

Foghorn Therapeutics
Foghorn Therapeutics

Cambridge, MA, US

Board Member· Board
Rome Therapeutics
Rome Therapeutics
Series B$199M642020Boston, MA, US
Board Member· Board

Leadership at Rome Therapeutics

Jay ParrishJay ParrishBoard Member
David TingDavid TingCo-Founder
Jeff HatfieldJeff HatfieldBoard Member
Rosana KapellerRosana KapellerCo-Founder
Kristina BurowKristina BurowBoard Member
Benjamin GreenbaumBenjamin GreenbaumCo-Founder

Similar to Rome Therapeutics

Kurome TherapeuticsKurome TherapeuticsCincinnati, OH, USCancer Treatmentsest. 2019Kurome TherapeuticsCincinnati, OH, US · est. 2019

Kurome Therapeutics: Pioneering pre-clinical cancer treatments targeting immune-resistant cells.

Series A · $15M30
Triplet TherapeuticsTriplet TherapeuticsCambridge, MA, USBiotechnologyest. 2019Triplet TherapeuticsCambridge, MA, US · est. 2019

Triplet Therapeutics: Pioneering biotech firm developing transformative treatments for genetic diseases.

Series A · $59M36
Remix TherapeuticsRemix TherapeuticsWatertown, MA, USTherapiesest. 2018Remix TherapeuticsWatertown, MA, US · est. 2018

Remix Therapeutics: A biotech firm innovating small molecule therapies to revolutionize disease treatment.

Series D · $211M71
Nextrna TherapeuticsNextrna TherapeuticsBoston, MA, USTherapeuticsest. 2020Nextrna TherapeuticsBoston, MA, US · est. 2020

NextRNA Therapeutics: Innovating RNA-directed therapeutics to combat disease-causing ncRNAs.

Series A · $56.1M33
Remix Therapeutics
Remix Therapeutics
Series D$211M712018Watertown, MA, US
Board Member· Board

Leadership at Remix Therapeutics

Matthew PattersonMatthew PattersonBoard Member
Kevin BittermanKevin BittermanBoard Member
Peter G. Smith CHSTPeter G. Smith CHSTFounder
Michael RomeMichael RomeBoard Member

Similar to Remix Therapeutics

Nextrna TherapeuticsNextrna TherapeuticsBoston, MA, USTherapeuticsest. 2020Nextrna TherapeuticsBoston, MA, US · est. 2020

NextRNA Therapeutics: Innovating RNA-directed therapeutics to combat disease-causing ncRNAs.

Series A · $56.1M33
ReviR TherapeuticsReviR TherapeuticsSan Francisco, CA, USMedicines, Therapeuticsest. 2021ReviR TherapeuticsSan Francisco, CA, US · est. 2021

ReviR Therapeutics: A genomics-based platform for developing innovative RNA-targeting medicines.

Seed · $20M27
Arrakis TherapeuticsArrakis TherapeuticsWaltham, MA, USMedicines, Therapeuticsest. 2015Arrakis TherapeuticsWaltham, MA, US · est. 2015

Waltham-based biotech firm specializing in innovative solutions for global health challenges.

Series B · $113M121
ReNAgade TherapeuticsReNAgade TherapeuticsCambridge, MA, USRNA Therapeuticsest. 2021ReNAgade TherapeuticsCambridge, MA, US · est. 2021

ReNAgade Therapeutics: Pioneering RNA-based solutions for disease treatment through innovative medication production.

Series A · $300M123

Scott Biller's Similar Executives & Operators

WILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · KakaoSong Ji-Ho 'DeanSong Ji-Ho 'DeanBoard Member · KakaoYun SeokYun SeokBoard Member · KakaoHong EuntaekHong EuntaekBoard Member · Kakao

People Similar to Scott Biller

Samuel L. BarkerSamuel L. BarkerBoard Member · Bio Green Med SolutionChris RamsborgChris RamsborgBoard Member · Inceptor BioMichael BoiceMichael BoiceCo-Founder · RepairogenChris O’DonnellChris O’DonnellBoard Member · Triana BiomedicinesPatrick HeimPatrick HeimBoard Member · PreemptGilad GlickGilad GlickBoard Member · Beta Bionics